Skip to content

RKTO

Hoth Therapeutics, Inc.

NASDAQ · Healthcare · Medical - Pharmaceuticals · US

$0.50
−1.97%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
+18.8%

Three-year CAGR

Revenue
—
EBITDA
—
EBIT
-35.2%
Net income
-52.3%
EPS
+29.7%
Free cash flow
-40.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026